The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Flagged first, then by citations
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 767
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking
Murphy, D. E., de Jong, O. G., Brouwer, M., Wood, M. J. A., Lavieu, G., Schiffelers, R. M., & Vader, P. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0223-5 · Cited by 732
van Zandwijk, N., Pavlakis, N., Kao, S. C.-H., Linton, A., Boyer, M. J., Clarke, S. J., Huynh, Y., Chrzanowska, A., FULHAM, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 727
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
Self-citationEfficient RNA drug delivery using red blood cell extracellular vesicles
Usman, W. M., Pham, T. C., Kwok, Y. Y., Vu, L. T., Ma, V., Peng, B., Chan, Y. S., Wei, L., Chin, S. M., Azad, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04791-8 · Cited by 663
Polyphenol‐Containing Nanoparticles: Synthesis, Properties, and Therapeutic Delivery
Guo, Y., Sun, Q., Wu, F., Dai, Y., & Chen, X. S. (2021) · Advanced Materials · doi:10.1002/adma.202007356 · Cited by 663
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05075-2 · Cited by 683
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 654
Therapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 625
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M. V., & Natarajan, R. D. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 615
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586
Yanez Arteta, M., Kjellman, T., Bartesaghi, S., Wallin, S., Wu, X., Kvist, A. J., Dabkowska, A., Székely, N., Radulescu, A., Bergenholtz, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720542115 · Cited by 534
Nie, Y., Li, D., Peng, Y., Wang, S., Hu, S., Liu, M., Ding, J., & Zhou, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119513 · Cited by 548
Alsaiari, S. K., Patil, S., Alyami, M., Alamoudi, K. O., Aleisa, F. A., Merzaban, J. S., Li, M., & Khashab, N. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11754 · Cited by 517
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 513
The growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Sun, Y., Lau, S. Y., Lim, Z. W., Chang, S. C., Ghadessy, F. J., Partridge, A. W., & Miserez, A. (2022) · Nature Chemistry · doi:10.1038/s41557-021-00854-4 · Cited by 426
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Călin, G. A., & Özpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 426
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
Therapeutic siRNA: State-of-the-Art and Future Perspectives
Friedrich, M., & Aigner, A. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 428
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Witzigmann, D., Kulkarni, J. A., Leung, J., Chen, S., Cullis, P. R., & van der Meel, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.026 · Cited by 376
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Polymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Chalarca, C. F. S., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 379
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
The approved gene therapy drugs worldwide: from 1998 to 2019
Ma, C.-C., Wang, Z.-L., Xu, T., He, Z.-Y., & Wei, Y.-Q. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107502 · Cited by 310
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 330
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 311
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
Brown, C. R., Gupta, S., Qin, J., Racie, T., He, G., Lentini, S., Malone, R., Yu, M., Matsuda, S., Shulga-Morskaya, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa670 · Cited by 285
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Morais, P., Adachi, H., & Yu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789427 · Cited by 281
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Wojnilowicz, M., Glab, A., Bertucci, A., Caruso, F., & Cavalieri, F. (2018) · ACS Nano · doi:10.1021/acsnano.8b05151 · Cited by 265
ARMMs as a versatile platform for intracellular delivery of macromolecules
Wang, Q., Yu, J., Kadungure, T., Beyene, J., Zhang, H., & Lu, Q. (2018) · Nature Communications · doi:10.1038/s41467-018-03390-x · Cited by 275
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 266
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Zolbanin, N. M., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 269
Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside
Sajid, M. I., Moazzam, M., Kato, S., Cho, K. Y., & Tiwari, R. K. (2020) · Pharmaceuticals · doi:10.3390/ph13100294 · Cited by 262
Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA
Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K. E., Mihai, C., Almarsson, Ö., & Sahay, G. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b02664 · Cited by 251
Therapeutic targeting of non-coding RNAs in cancer
Slabý, O., Laga, R., & Sedláček, O. (2017) · Biochemical Journal · doi:10.1042/bcj20170079 · Cited by 252
The uptake of metal–organic frameworks: a journey into the cell
Linnane, E., Haddad, S., Melle, F., Mei, Z., & Fairen‐Jiménez, D. (2022) · Chemical Society Reviews · doi:10.1039/d0cs01414a · Cited by 234
Functional siRNA Delivery by Extracellular Vesicle–Liposome Hybrid Nanoparticles
Evers, M. J. W., van de Wakker, S. I., de Groot, E. M., de Jong, O. G., Gitz-Francois, J. J., Seinen, C. W., Sluijter, J. P. G., Schiffelers, R. M., & Vader, P. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101202 · Cited by 229
Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake
Zhao, X., Wu, D., Ma, X., Wang, J., Hou, W., & Zhang, W. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110237 · Cited by 197
Kaczmarek, J. C., Kauffman, K. J., Fenton, O. S., Sadtler, K., Patel, A. K., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b02917 · Cited by 218
Nanotechnology-based strategies for siRNA brain delivery for disease therapy
Zheng, M., Tao, W., Zou, Y., Farokhzad, O. C., & Shi, B. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.006 · Cited by 210
Tapping the RNA world for therapeutics
Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 202
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Huldt, C. W., Andersson, E.-M., Valeur, E., Jansson‐Löfmark, R., Janzén, D. L. I., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 191
Poly(β‐Amino Esters): Synthesis, Formulations, and Their Biomedical Applications
Liu, Y., Li, Y., Keskin, D., & Shi, L. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201801359 · Cited by 192
Circular RNAs as Therapeutic Agents and Targets
Holdt, L. M., Kohlmaier, A., & Teupser, D. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01262 · Cited by 189
Wang, Y., Xie, Y., Kilchrist, K. V., Li, J., Duvall, C. L., & Oupický, D. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21214 · Cited by 176
Nanocarrier‐Mediated Cytosolic Delivery of Biopharmaceuticals
He, W., Xing, X., Wang, X., Wu, D., Wu, W., Guo, J., & Mitragotri, S. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910566 · Cited by 179
Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy
Zhan, Q., Yi, K., Qi, H., Li, S., Li, X., Wang, Q., Wang, Y., Liu, C., Qiu, M., Yuan, X., et al. (2020) · Theranostics · doi:10.7150/thno.45028 · Cited by 168
Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery
Herrera‐Barrera, M., Kim, J., Eygeris, Y., Jozić, A., & Sahay, G. (2021) · Biomaterials Science · doi:10.1039/d0bm01947j · Cited by 180
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Aptamers: Uptake mechanisms and intracellular applications
Yoon, S., & Rossi, J. J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.003 · Cited by 171
Green Tea Catechin Dramatically Promotes RNAi Mediated by Low-Molecular-Weight Polymers
Shen, W., Wang, Q., Shen, Y., Gao, X., Li, L., Yan, Y., Wang, H., & Cheng, Y. (2018) · ACS Central Science · doi:10.1021/acscentsci.8b00363 · Cited by 169
Murphy, D. E., de Jong, O. G., Evers, M. J. W., Nurazizah, M., Schiffelers, R. M., & Vader, P. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00094 · Cited by 169
Protein Cages: From Fundamentals to Advanced Applications
Edwardson, T. G. W., Levasseur, M. D., Tetter, S., Steinauer, A., Hori, M., & Hilvert, D. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00877 · Cited by 171
Kang, H., Ga, Y. J., Kim, S. H., Cho, Y. H., Kim, J., Kim, C., & Yeh, J. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00981-9 · Cited by 177
Milk-Derived Extracellular Vesicles in Inter-Organism, Cross-Species Communication and Drug Delivery
Sanwlani, R., Fonseka, P., Chitti, S. V., & Mathivanan, S. (2020) · Proteomes · doi:10.3390/proteomes8020011 · Cited by 170
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01551 · Cited by 163
RNA therapy: Are we using the right molecules?
Yu, A., Jian, C., Yu, A. H., & Tu, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.011 · Cited by 167
High-Throughput Analysis Reveals Rules for Target RNA Binding and Cleavage by AGO2
Becker, W. R., Ober-Reynolds, B., Jouravleva, K., Jolly, S. M., Zamore, P. D., & Greenleaf, W. J. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.06.012 · Cited by 161
Cheng, Y., Sun, C., Liu, R., Yang, J., Dai, J., Zhai, T., Lou, X., & Xia, F. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901527 · Cited by 161
BBB pathophysiology–independent delivery of siRNA in traumatic brain injury
Li, W., Qiu, J., Li, X.-L., Aday, S., Zhang, J., Conley, G., Xu, J., Joseph, J., Lan, H., Langer, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6889 · Cited by 160
Delivery of RNA Therapeutics: The Great Endosomal Escape!
Dowdy, S. F., Setten, R. L., Cui, X.-S., & Jadhav, S. G. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0004 · Cited by 164
Self-citationChemical modifications of nucleic acid drugs and their delivery systems for gene‐based therapy
Chen, C., Yang, Z., & Tang, X. (2018) · Medicinal Research Reviews · doi:10.1002/med.21479 · Cited by 164
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Dowdy, S. F. (2023) · RNA · doi:10.1261/rna.079507.122 · Cited by 171
Self-citationXia, H., Wu, Y., Zhao, J., Cheng, C., Lin, J., Yang, Y., Lu, L., Xiang, Q., Bian, T., & Liu, Q. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01138-9 · Cited by 159
Sustainability Challenges and Opportunities in Oligonucleotide Manufacturing
Andrews, B. I., Antia, F. D., Brueggemeier, S. B., Diorazio, L. J., Koenig, S. G., Kopach, M. E., Lee, H., Olbrich, M., & Watson, A. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c02291 · Cited by 156
Munson, M. J., O’Driscoll, G., da Silva, A. M., Lázaro‐Ibáñez, E., Gallud, A., Wilson, J. T., Collén, A., Esbjörner, E. K., & Sabirsh, A. (2021) · Communications Biology · doi:10.1038/s42003-021-01728-8 · Cited by 160
Methodologies to Isolate and Purify Clinical Grade Extracellular Vesicles for Medical Applications
Akbar, A., Malekian, F., Baghban, N., Kodam, S. P., & Ullah, M. (2022) · Cells · doi:10.3390/cells11020186 · Cited by 156
Where should siRNAs go: applicable organs for siRNA drugs
Ahn, I., Kang, C. S., & Han, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00998-y · Cited by 162
Functional sequestration of microRNA-122 from Hepatitis C Virus by circular RNA sponges
Jost, I., Shalamova, L. A., Gerresheim, G. K., Niepmann, M., Bindereif, A., & Roßbach, O. (2018) · RNA Biology · doi:10.1080/15476286.2018.1435248 · Cited by 150
Graczyk, A., Pawłowska, R., Jędrzejczyk, D., & Chworoś, A. (2020) · Molecules · doi:10.3390/molecules25010204 · Cited by 154
Editorial focus: understanding off-target effects as the key to successful RNAi therapy
Bartoszewski, R., & Sikorski, A. F. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0196-3 · Cited by 157
Exosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery
Drescher, S., & van Hoogevest, P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121235 · Cited by 157
MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target
Mellis, D. J., & Caporali, A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20170037 · Cited by 141
Improving siRNA Delivery In Vivo Through Lipid Conjugation
Osborn, M. F., & Khvorova, A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0725 · Cited by 137
Nanomaterials for Therapeutic RNA Delivery
Han, X., Mitchell, M. J., & Nie, G. (2020) · Matter · doi:10.1016/j.matt.2020.09.020 · Cited by 139
miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype
Chin, D. D., Poon, C. J., Wang, J., Joo, J., Ong, V., Jiang, Z., Cheng, K., Plotkin, A., Magee, G. A., & Chung, E. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120810 · Cited by 138
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 143
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., Strooper, B. D., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 137
Guan, S., Munder, A., Hedtfeld, S., Braubach, P., Glage, S., Zhang, L., Lienenklaus, S., Schultze, A., Hasenpusch, G., Garrels, W., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0358-x · Cited by 130
Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI
Tang, T., Wang, B., Li, Z., Wen, Y., Feng, S., Wu, M., Liu, D., Cao, J.-Y., Yin, Q., Yin, D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020111561 · Cited by 129
How do oral insecticidal compounds cross the insect midgut epithelium?
Denecke, S., Swevers, L., Douris, V., & VONTAS, J. G. (2018) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2018.10.005 · Cited by 125
Biodegradable Cationic and Ionizable Cationic Lipids: A Roadmap for Safer Pharmaceutical Excipients
Jörgensen, A. M., Wibel, R., & Bernkop‐Schnürch, A. (2023) · Small · doi:10.1002/smll.202206968 · Cited by 131
Targeting RNA in mammalian systems with small molecules
Donlic, A., & Hargrove, A. E. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1477 · Cited by 122
Ma, D., Bian, H., Gu, M., Wang, L., Chen, X., & Peng, X. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215677 · Cited by 124
Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don’t
Juliano, R. L. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0727 · Cited by 125
Kilchrist, K. V., Dimobi, S. C., Jackson, M. A., Evans, B. C., Werfel, T. A., Dailing, E. A., Bedingfield, S. K., Kelly, I. B., & Duvall, C. L. (2019) · ACS Nano · doi:10.1021/acsnano.8b05482 · Cited by 124
Extracellular vesicles as delivery systems at nano-/micro-scale
Fu, P., Zhang, J., Li, H., Mak, M., Xu, W., & Tao, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113910 · Cited by 121
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
